PMID: 3746543Sep 1, 1986Paper

Transplacental passage of intravenous immunoglobulin in the last trimester of pregnancy

The Journal of Pediatrics
D SidiropoulosS Barandun

Abstract

Immunoglobulin G was given intravenously (IVIgG) to pregnant women (27 to 36 weeks gestation) with signs of chorioamnionitis who were at risk for preterm delivery. Twenty-four patients received antibiotics alone (control group). Twenty-seven patients received the same antibiotics in combination with IVIgG, either 12 gm in 12 hours (low IVIgG dosage) or 24 gm on each of 5 consecutive days (high IVIgG dosage). Transplacental passage of IVIgG was shown to be a function of gestational age and of dose. Up to the thirty-second week of gestation, IgG infusions had no effect on IgG concentrations in cord sera. After that time, cord serum IgG levels were significantly higher in the high-dose group compared with the low-dose and control groups. All four subclasses of IgG, and two different antibodies present in the IVIgG preparation passed from the mother to the fetus. Thus the infused IgG mimicked the transplacental passage of endogenous IgG.

References

Nov 15, 1985·American Journal of Obstetrics and Gynecology·F DaffosF Forestier
Dec 1, 1971·Vox Sanguinis·A MorellM Kleemola
Mar 30, 1984·The American Journal of Medicine·R U SorensenS H Polmar
Oct 1, 1981·Placenta·P M Johnson, P J Brown

❮ Previous
Next ❯

Citations

Jan 1, 1994·International Journal of Technology Assessment in Health Care·R A InselM Pichichero
Nov 24, 1988·The New England Journal of Medicine·J B BusselU Chitkara
Feb 12, 1998·American Journal of Reproductive Immunology : AJRI·M Palfi, A Selbing
May 29, 1998·American Journal of Reproductive Immunology : AJRI·M PalfiA Selbing
May 1, 1994·Archives of Disease in Childhood. Fetal and Neonatal Edition·B A AcunasD Vergani
Jun 3, 2000·Annual Review of Immunology·V Ghetie, E S Ward
Aug 26, 1998·Emerging Infectious Diseases·G H Cassell
Mar 31, 2009·The Journal of Emergency Medicine·Yael Lurie, Yedidia Bentur
Feb 18, 2014·Journal of the American Academy of Dermatology·Jenny E MuraseDaniel C Butler
Oct 30, 2004·Journal of Obstetrics and Gynaecology : the Journal of the Institute of Obstetrics and Gynaecology·N VitoratosG Creatsas
Dec 1, 1993·British Journal of Obstetrics and Gynaecology·E ShalevD Peleg

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.